Effect of PCSK9 inhibition with evolocumab on lipoprotein subfractions in familial dysbetalipoproteinemia (type III hyperlipidemia)
E Waldmann, L Wu, K Busygina, J Altenhofer, K Henze… - PloS one, 2022 - journals.plos.org
Background and aims Familial dysbetalipoproteinemia (FDBL) is a rare inborn lipid disorder
characterized by the formation of abnormal triglyceride-and cholesterol-rich lipoproteins …
characterized by the formation of abnormal triglyceride-and cholesterol-rich lipoproteins …
[引用][C] Alirocumab, a fully human monoclonal antibody to PCSK9, reduces high plasma Lp (a) concentration: pooled analysis of 352 patients from phase 2
D Gaudet, D Kereiakes, J McKenney… - Journal of Clinical …, 2013 - lipidjournal.com
Synopsis Lipoprotein (a)[Lp (a)] is an independent risk factor for cardiovascular disease,
with cardiovascular risk increased at Lp (a) levels> 30 mg/dL. Of currently available …
with cardiovascular risk increased at Lp (a) levels> 30 mg/dL. Of currently available …
Clinical efficacy and safety of achieving very low LDL-cholesterol concentrations with the PCSK9 inhibitor evolocumab: a prespecified secondary analysis of the …
RP Giugliano, TR Pedersen, JG Park, GM De Ferrari… - The Lancet, 2017 - thelancet.com
Background LDL cholesterol is a well established risk factor for atherosclerotic
cardiovascular disease. How much one should or safely can lower this risk factor remains …
cardiovascular disease. How much one should or safely can lower this risk factor remains …
Effect of different types and dosages of proprotein convertase subtilisin/kexin type 9 inhibitors on lipoprotein (a) levels: a network meta-analysis
Z Yu, L Hu, C Sun, Z Wang, X Zhang… - Journal of …, 2023 - journals.lww.com
Abstract Lipoprotein (a)[Lp (a)] has become an important component of the residual risk of
cardiovascular diseases. Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors …
cardiovascular diseases. Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors …
[HTML][HTML] Pharmacokinetic and pharmacodynamic assessment of alirocumab in patients with familial hypercholesterolemia associated with proprotein convertase …
PN Hopkins, M Krempf, E Bruckert, S Donahue… - Journal of clinical …, 2019 - Elsevier
Background Familial hypercholesterolemia is characterized by high levels of low-density
lipoprotein cholesterol (LDL-C), and causes of familial hypercholesterolemia include …
lipoprotein cholesterol (LDL-C), and causes of familial hypercholesterolemia include …
[PDF][PDF] Does evolocumab, as a PCSK9 inhibitor, ameliorate the lipid profile in familial hypercholesterolemia patients? A meta-analysis of randomized controlled trials
Proprotein convertase subtilisin-kexin type 9 (PCSK9) is a member of regulatory serine
proteases which is mostly expressed in liver. In the physiological condition, LDL-C binds to …
proteases which is mostly expressed in liver. In the physiological condition, LDL-C binds to …
[HTML][HTML] Time-averaged low-density lipoprotein cholesterol lowering with evolocumab: pooled analysis of phase 2 trials
B Schludi, RP Giugliano, MS Sabatine, FJ Raal… - Journal of Clinical …, 2022 - Elsevier
LDL-C is the pivotal risk factor for atherosclerotic cardiovascular disease, and the benefit
from LDL-C lowering is proportional to the magnitude of reduction. Clinical trials …
from LDL-C lowering is proportional to the magnitude of reduction. Clinical trials …
Clinical utility of evolocumab in the management of hyperlipidemia: patient selection and follow-up
Inhibition of PCSK9 is a novel therapeutic strategy aimed at reducing low-density-lipoprotein
cholesterol (LDL-C) and cardiovascular risk. Evolocumab is a fully humanized monoclonal …
cholesterol (LDL-C) and cardiovascular risk. Evolocumab is a fully humanized monoclonal …
Design and rationale of the GAUSS‐2 study trial: a double‐blind, ezetimibe‐controlled phase 3 study of the efficacy and tolerability of evolocumab (AMG 145) in …
L Cho, M Rocco, D Colquhoun, D Sullivan… - Clinical …, 2014 - Wiley Online Library
Statins effectively lower low‐density lipoprotein cholesterol (LDL‐C), reducing
cardiovascular morbidity and mortality. Most patients tolerate statins well, but approximately …
cardiovascular morbidity and mortality. Most patients tolerate statins well, but approximately …